Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 4Phase 1/2 4Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 1Lymphoma 1

Interventions

Doxorubicin 310-propargyl-10-deazaaminopterin 3Vincristine 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Gemcitabine 2Drug Therapy 2Cyclophosphamide 2Alemtuzumab 2romidepsin 1cc-486 1belinostat 1Vitamin B 12 1Stem Cell Transplantation 1Standard of Care 1Specimen Handling 1Prednisone 1Practice Guidelines as Topic 1Melphalan 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Hematopoietic Stem Cell Mobilization 1Folic Acid 1Etoposide 1Cytarabine 1Cladribine 1Carmustine 1Busulfan 1Brentuximab Vedotin 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, T-Cell × romidepsin × Clear all
NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Celgene

Phase 3 Active not recruiting
93 enrolled 19 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡